18q11.2-q12.1染色体缺失可预测贝伐珠单抗治疗的转移性结直肠癌生存
本研究在Angiopredict(96例)和MOMA(81例)两个接受贝伐珠单抗一线治疗的转移性结直肠癌队列中验证染色体拷贝数缺失与疗效的关系,并以90例未接受贝伐珠单抗的患者及CAIRO队列作为对照。结果显示18q11.2-q12.1缺失与更长的无进展生存期显著相关,且与总生存期和客观缓解率的改善相关。
要点
- 18q11.2-q12.1缺失与接受贝伐珠单抗患者的PFS延长显著相关。
- 该缺失在未接受贝伐珠单抗的患者中未见类似预测作用。
- 该缺失与OS和客观缓解率改善相关,支持其作为贝伐珠单抗疗效预测标志物。
核心结论
- 18q11.2-q12.1染色体缺失可稳定预测接受贝伐珠单抗治疗的mCRC患者PFS延长。
- 该缺失对OS和客观缓解率的预测价值在合并CAIRO2队列后达到显著。
研究设计与样本
- 研究分析了Angiopredict研究96例和MOMA研究81例接受贝伐珠单抗一线治疗的mCRC患者原发肿瘤样本。
- 另分析90例未接受贝伐珠单抗的mCRC患者样本作为对照,并与此前CAIRO2和CAIRO队列结果比较。
- 采用浅层全基因组测序检测肿瘤活检标本的拷贝数异常,并与PFS、OS和缓解情况关联分析。
主要发现
- 两个贝伐珠单抗队列中该缺失与OS和总缓解率呈类似关联,合并CAIRO2队列后达显著。
- 未接受贝伐珠单抗的队列及CAIRO队列的中位PFS与无18q11.2-q12.1缺失的APD、MOMA、CAIRO2患者相似。
临床怎么用
- 检测mCRC原发肿瘤18q11.2-q12.1缺失有助于筛选可能从贝伐珠单抗联合化疗中显著获益的患者。
- 该标志物有望用于贝伐珠单抗一线治疗决策,但需进一步前瞻性验证后再常规应用。
局限性
- 验证队列样本量有限(APD 96例、MOMA 81例),对照队列仅90例。
- OS和缓解率的显著性需合并CAIRO2队列后才成立,独立验证证据不足。
- 原文未报告检测方法的具体阈值和前瞻性干预设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for a biomarker of response to bevacizumab. Previously, we demonstrated that losses of chromosomes 5q34, 17q12, and 18q11.2-q12.1 had a significant correlation with progression-free survival (PFS) in patients with mCRC treated with bevacizumab in the CAIRO2 clinical trial but not in patients who did not receive bevacizumab in the CAIRO trial. This study was designed to validate these findings. Materials and Methods Primary mCRC samples were analyzed from two cohorts of patients who received bevacizumab as first-line treatment; 96 samples from the European multicenter study Angiopredict (APD) and 81 samples from the Italian multicenter study, MOMA. A third cohort of 90 samples from patients with mCRC who did not receive bevacizumab was analyzed. Copy number aberrations of tumor biopsy specimens were measured by shallow whole-genome sequencing and were correlated with PFS, overall survival (OS), and response. Results Loss of chromosome 18q11.2-q12.1 was associated with prolonged PFS most significantly in both the cohorts that received bevacizumab (APD: hazard ratio, 0.54; P = .01; PFS difference, 65 days; MOMA: hazard ratio, 0.55; P = .019; PFS difference, 49 days). A similar association was found for OS and overall response rate in these two cohorts, which became significant when combined with the CAIRO2 cohort. Median PFS in the cohort of patients with mCRC who did not receive bevacizumab and in the CAIRO cohort was similar to that of the APD, MOMA, and CAIRO2 patients without an 18q11.2-q12.1 loss. Conclusion We conclude that the loss of chromosome 18q11.2-q12.1 is consistently predictive for prolonged PFS in patients receiving bevacizumab. The predictive value of this loss is substantiated by a significant gain in OS and overall response rate.
引用
- van Dijk E, Biesma HD, Cordes M, et al. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. J Clin Oncol. 2018. PMID: 29792754. doi:10.1200/JCO.2017.77.1782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。